Stonebridge Financial Group LLC Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stonebridge Financial Group LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 410 shares of the pharmaceutical company’s stock, valued at approximately $165,000.

Other hedge funds have also made changes to their positions in the company. Summit Trail Advisors LLC increased its stake in Vertex Pharmaceuticals by 35.1% in the fourth quarter. Summit Trail Advisors LLC now owns 4,409 shares of the pharmaceutical company’s stock valued at $1,776,000 after purchasing an additional 1,145 shares during the last quarter. Sapient Capital LLC grew its holdings in Vertex Pharmaceuticals by 1.4% in the 4th quarter. Sapient Capital LLC now owns 35,796 shares of the pharmaceutical company’s stock valued at $14,415,000 after buying an additional 498 shares during the period. Wingate Wealth Advisors Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $43,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its holdings in shares of Vertex Pharmaceuticals by 5.2% during the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 694 shares of the pharmaceutical company’s stock worth $308,000 after acquiring an additional 34 shares during the period. Finally, Howland Capital Management LLC boosted its position in shares of Vertex Pharmaceuticals by 2.3% in the fourth quarter. Howland Capital Management LLC now owns 1,725 shares of the pharmaceutical company’s stock worth $695,000 after acquiring an additional 39 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares of the company’s stock, valued at $29,438,776.43. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

VRTX has been the subject of several research analyst reports. Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. Truist Financial increased their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a “buy” rating in a research report on Tuesday. StockNews.com cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. Canaccord Genuity Group upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and raised their price objective for the stock from $408.00 to $424.00 in a report on Tuesday. Finally, William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Ten analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $505.96.

Vertex Pharmaceuticals Stock Down 0.4 %

VRTX stock opened at $453.20 on Thursday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $435.91 and a 200-day simple moving average of $461.85. The company has a market capitalization of $116.71 billion, a P/E ratio of -227.74, a PEG ratio of 1.80 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.94 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.